pharma news

News

Novartis' oral BTK drug moves the needle in CINDU

Novartis is set to expand the label for its oral BTK inhibitor Rhapsido, keeping the drug on course to become one of its biggest-ever brands.

News

NICE backs first disease-modifying drug for ARG1 deficiency

Immedica's Loargys is poised to become the first NHS therapy for ultra-rare genetic disorder ARG1 deficiency that can alter the course of the disease.

News

NHS study will pick apart mental illness with data science

Volunteers with schizophrenia, bipolar, and depression will take part in an NHS study that will use genetic and health data to find new therapies.

News

Compass points to strong psilocybin data in depression

Armed with new data, Compass wants to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression.

News

EU approval for new asthma drug Exdensur lifts GSK

EU approval takes GSK a step closer to fulfilling its blockbuster sales hopes for new long-acting respiratory drug Exdensur.

News

Mark Dawson named head of Roche's pRED unit

Roche has appointed leading Australian cancer researcher Mark Dawson to lead its pRED R&D division, as the company prepares for a steep patent cliff.

Novartis' oral BTK drug moves the needle in CINDU

NICE backs first disease-modifying drug for ARG1 deficiency

NHS study will pick apart mental illness with data science

Compass points to strong psilocybin data in depression

EU approval for new asthma drug Exdensur lifts GSK

Mark Dawson named head of Roche's pRED unit

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

pharma news

Editor's Picks